| 2024-10-01 | +2.97 % |
|
| 2024-09-30 | +0.41 % |
|
| 2024-09-27 | +1.07 % |
|
| 2024-09-26 | +3.02 % |
|
| 2024-09-24 | -0.66 % |
|
| 2024-08-15 | +0.82 % |
|
| 2024-08-07 | -1.6 % |
|
| 2024-08-01 | -1 % |
|
| 2024-07-12 | +2.2 % |
|
| 2024-07-11 | +2.57 % |
- The article discusses Eric S. Yuan, the CEO of Zoom Video Communications, selling a significant portion of his company stock, while Incyte (INCY) stock went up by 2.57% the previous night. The increase in Incyte (INCY) stock may be attributed to investors' interest in the company following various trading moves by influential entities, such as ARK ETFs, and the positive outlook on the biotech sector.
- The article discusses Cathie Wood's ARK ETFs making significant moves in the stock market, including selling a portion of their position in Incyte Corp (NASDAQ:INCY), with Incyte stock going up by 2.57% likely due to other strategic buys and sells made by the fund in biotech and technology sectors.
- The article reports that Incyte Corp (NASDAQ:INCY) stock was up 2.57% following a significant insider transaction, where one of its top executives sold shares at $60.00 per share, worth $488,880, and the stock has seen increases attributed to various positive factors like share repurchases, financial stability, revenue growth, and potential investment value.
|
| 2024-07-10 | +0.05 % |
|
| 2024-07-09 | +4.35 % |
|
| 2024-07-02 | -3.04 % |
|
| 2024-06-26 | -2.14 % |
|
| 2024-06-14 | -0.93 % |
|
| 2024-06-13 | +4.59 % |
- Summary: The article discusses the positive performance of the Nasdaq 100 and S&P 500 indices, driven by tech stocks, with Incyte Corporation (INCY) stock notably rising by 4.57%, likely due to market expectations of interest rate cuts, optimism from U.S. Treasury Secretary Janet Yellen regarding disinflation progress, and overall positive sentiment towards risky assets.
Reason for INCY stock going up: Market optimism about continued progress in disinflation, anticipation of interest rate cuts in September, and positive sentiment towards risky assets contributed to the 4.57% increase in Incyte Corporation (INCY) stock.
- The article mentions that Incyte(INCY) stock was up by 4.59% last night, and the reason for the increase in Incyte(INCY) stock could be due to positive news, a strong earnings report, or an overall positive market sentiment.
- The article provides details on Incyte Corporation's successful completion of a modified "Dutch auction" tender offer, with final results indicating the company's repurchase of approximately 12.4% of its outstanding shares of common stock, leading to a surge in its stock price by 4.59%, due to positive investor sentiment towards the buyback and potential future stock purchase agreements.
|
| 2024-06-10 | +0.41 % |
|
| 2024-06-07 | +1.28 % |
|
| 2024-06-04 | -0.39 % |
|
| 2024-05-15 | |
|
| 2024-05-14 | -0.95 % |
|
| 2024-05-13 | +8.56 % |
|
| 2024-05-10 | -0.82 % |
|
| 2024-05-09 | -0.02 % |
|
| 2024-05-07 | +0.54 % |
|
| 2024-05-06 | +0.6 % |
|
| 2024-05-03 | +1.26 % |
|
| 2024-05-02 | +0.28 % |
|
| 2024-04-30 | -0.97 % |
|
| 2024-04-29 | +1.7 % |
- The article discusses MorphoSys AG's first quarter financial results for 2024 and the proposed acquisition by Novartis, contributing to the 1.7% increase in Incyte (INCY) stock as it had previously acquired tafasitamab rights from MorphoSys, leading to positive developments regarding the company's oncology programs, financial outlook, and future research initiatives.
- The article reports that Incyte (INCY) stock went up by 1.7% due to the company entering into a business combination agreement to be acquired by Novartis for €68.00 per share in cash, representing a total equity value of €2.7 billion, receiving all mandatory antitrust approvals for the proposed acquisition, and shareholder acceptance period for the Novartis offer commencing.
- The article discusses the case of SEC v. Panuwat, where the Securities and Exchange Commission (SEC) successfully applied a legal theory called "shadow" insider trading, showcasing a scenario where trading securities in one company (Company B) based on material non-public information from another company (Company A) was considered illegal. The SEC's argument focused on the "market connection" between the two entities, expanding the scope of insider trading beyond direct materiality to the traded company to include broader market implications. The stock of Incyte (INCY) went up due to the SEC's novel theory of insider trading, which hinges on economic correlation between companies in the same sector and breach of duty by individuals possessing material non-public information. This expansion of insider trading law through litigation raised concerns about its potential impact on efficient price discovery in the market and calls for review and updating of corporate policies by compliance officers.
|
| 2024-04-26 | +0.98 % |
- The article discusses how Handelsbanken Fonder AB reduced its stake in Incyte (INCY) by 19.1%, leading to a slight increase in the stock price, and the increase in holdings by other institutional investors like Pacer Advisors Inc., Los Angeles Capital Management LLC, Acadian Asset Management LLC, Federated Hermes Inc., and Royal Bank of Canada contributed to the positive sentiment towards the company, pushing the stock's value up by 0.98%.
- The article discusses Repare Therapeutics Inc. appointing Dr. Steven H. Stein to its Board of Directors from Incyte Corporation. Incyte (INCY) stock likely went up due to positive market sentiment surrounding Repare's expansion of cancer treatments and the addition of Dr. Stein's expertise, despite Repare facing financial challenges.
- The article discusses how Incyte (INCY) stock price rose by 0.98% and reports on a recent price objective reduction by investment analysts at Oppenheimer, who lowered their target price from $92.00 to $84.00 while maintaining an "outperform" rating on the biopharmaceutical company. The stock increase could be attributed to Oppenheimer's price target suggesting a potential upside of 64.13% from the current price, along with various other equities analysts providing positive ratings and target price increases for Incyte, indicating investor confidence in the company's future performance.
|
| 2024-04-24 | +0.17 % |
|
| 2024-04-23 | -0.52 % |
|
| 2024-04-16 | -0.39 % |
|
| 2024-04-15 | -0.78 % |
|
| 2024-04-11 | -0.15 % |
|
| 2024-04-10 | -0.54 % |
|
| 2024-04-08 | -0.34 % |
|
| 2024-04-05 | +0.45 % |
|
